NCT04289974View on ClinicalTrials.gov

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

UnknownOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

April 30, 2022

Conditions

Breast Cancer

Interventions

DRUG

Palbociclib

Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)

Trial Locations (1)

100021

RECRUITING

Cancer Hospital, ChineseAMS, Beijing